As of Friday close, Roivant Sciences Ltd.’s (NASDAQ:ROIV) stock was up $0.2, moving up 2.35 percent to $8.70. The average number of shares traded per day over the past five days has been 4,702,620 shares. 3 times new highs have been achieved over the past 5 days, with a $1.05 gain in that time frame. In the last twenty days, the average volume was 2,514,680, while in the previous 50 days, it was 2,637,150.
Since last month, ROIV stock retreated -2.25%. Shares of the company fell to $7.50 on 03/10/23, the lowest level in the past month. A 52-week high of $10.00 was reached on 01/12/23 after having rallying from a 52-week low of $2.52. Since the beginning of this year, ROIV’s stock price has risen by 8.89% or $0.71, and marked a new high 7 times. However, the stock has declined by -13.00% since its 52-week high.
Do You Know The Best Place To Find Gains In Volatile Markets?
In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.
Click here for full details and to join for free.
ROIV stock investors should be aware that Roivant Sciences Ltd. (ROIV) stock had its last reported insider trading activity 17 days ago on Mar 01. Pulik Richard, the CFO of the company, disposed of 1,912 shares for $8.08 on Mar 01. It resulted in a $15,449 divestment by the insider. Ramaswamy Vivek sold 4,000,000 shares at an average price of $7.95 on Feb 22. The insider now owns 54,409,211 shares following the transaction. On Jan 05, President & COO Venker Eric sold 24,037 shares at $8.02 apiece. The transaction was valued at $192,777.
In the three months ended September 29, Roivant Sciences Ltd.’s quick ratio stood at 6.70, while its current ratio was 6.70, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending September 29 was 0.39, and the total debt-to-equity ratio was 0.43. On the profitability front, the trailing twelve-month gross margin is 78.20% percent. Based on annual data, ROIV earned $46.32 million in gross profit and brought in $55.29 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -68.60%. Return on equity (ROE) for the past 12 months was -96.60%.
In Roivant Sciences Ltd.’s quarter-end financial report for September 29, it reported total debt of $375.12 million. According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. ROIV’s revenue fell -42.76% to $12.53 million during the quarter, while net income inched up to $17.05 million. While analysts expected Roivant Sciences Ltd. to report -$0.42 quarterly earnings, the actual figure was -$0.42 per share. During the quarter, the company generated -$372.93 million in EBITDA. The liabilities of Roivant Sciences Ltd. were 775.82 million at the end of its most recent quarter ended September 29, and its total debt was $477.3 million. The value of shareholders’ equity is $758.43 million.
This quick technical analysis looks at Roivant Sciences Ltd.’s (ROIV) price momentum. With a historical volatility rate of 60.80%, the RSI 9-day stood at 64.15% on 17 March.
With respect to its five-day moving average, the current Roivant Sciences Ltd. price is up by +13.73% percent or $1.05. At present, ROIV shares trade -0.34% below its 20-day simple moving average and +95.95% percent above its 100-day simple moving average. However, the stock is currently trading approximately +15.08% above its SMA50 and +95.95% above its SMA200.
Stochastic coefficient K was 76.35% and Stochastic coefficient D was 65.21%, while ATR was 0.46. Given the Stochastic reading of 83.54% for the 14-day period, the RSI (14) reading has been calculated as 59.03%. As of today, the MACD Oscillator reading stands at 0.45, while the 14-day reading stands at 0.50.
JP Morgan launched its rating on Roivant Sciences Ltd. (NASDAQ: ROIV) to an Overweight in a note to investors on October 27, 2022. Roivant Sciences Ltd. (ROIV) has been rated Buy by analysts. According to 0 brokerage firms, ROIV is a sell, and 0 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Roivant Sciences Ltd. stock as buy, with 9 recommending it as overweight.
With a median target price of $13.50, the current consensus forecast for the stock is $10.00 – $19.00. Based on these forecasts, analysts predict Roivant Sciences Ltd. (ROIV) will achieve an average price target of $13.63.